• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Keros Therapeutics Reports Second Quarter 2024 Financial Results

    8/7/24 4:01:00 PM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KROS alert in real time by email

    LEXINGTON, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today reported financial results for the quarter ended June 30, 2024.

    "Keros continued to build upon the progress of all programs across our pipeline in the second quarter of 2024, as evidenced by our recent positive regulatory and data updates from the elritercept (KER-050) program," said Jasbir S. Seehra, Ph.D., Chair and Chief Executive Officer. "We continue to be excited by the strong enrollment activity we have seen to date in our Phase 2 clinical trial of cibotercept (KER-012) in patients with pulmonary arterial hypertension and look forward to completing enrollment of that trial in the fourth quarter of this year."

    Second Quarter 2024 Financial Results

    Keros reported a net loss of $45.3 million in the second quarter of 2024 as compared to a net loss of $37.5 million in the second quarter of 2023. The increase of $7.8 million for the second quarter was largely due to increased research and development efforts as well as additional investments to support the achievement of Keros' clinical and corporate goals.

    Research and development expenses were $40.5 million for the second quarter of 2024 as compared to $32.5 million for the same period in 2023. The increase of $8.0 million was primarily due to additional research and development efforts, manufacturing activities and personnel expenses to support the advancement of Keros' pipeline.

    General and administrative expenses were $10.0 million for the second quarter of 2024 as compared to $8.8 million for the same period in 2023. The increase of $1.2 million was primarily due to increase in personnel expenses and other external expenses to support Keros' organizational growth.

    Keros' cash and cash equivalents as of June 30, 2024 was $405.9 million compared to $331.1 million as of December 31, 2023. Keros expects that the cash and cash equivalents it had on hand at June 30, 2024 will enable Keros to fund its operating expenses and capital expenditure requirements into 2027.

    About Keros Therapeutics, Inc.

    Keros is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the TGF-ß family of proteins. We are a leader in understanding the role of the TGF-ß family of proteins, which are master regulators of the growth, repair and maintenance of a number of tissues, including blood, bone, skeletal muscle, adipose and heart tissue. By leveraging this understanding, we have discovered and are developing protein therapeutics that have the potential to provide meaningful and potentially disease-modifying benefit to patients. Keros' lead product candidate, elritercept (KER-050), is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and in patients with myelofibrosis. Keros' second product candidate, cibotercept (KER-012), is being developed for the treatment of pulmonary arterial hypertension and for the treatment of cardiovascular disorders. Keros' third product candidate, KER-065, is being developed for the treatment of obesity and for the treatment of neuromuscular diseases.

    Cautionary Note Regarding Forward-Looking Statements

    Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as "enable," "expects," "look forward," "progress" and "will" or similar expressions are intended to identify forward-looking statements. Examples of these forward-looking statements include statements concerning: Keros' expectations regarding its growth, strategy, progress and the design, objectives and timing of its clinical trials for elritercept and cibotercept, including its regulatory plans; and Keros' expected cash runway. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others: Keros' limited operating history and historical losses; Keros' ability to raise additional funding to complete the development and any commercialization of its product candidates; Keros' dependence on the success of its product candidates, elritercept, cibotercept and KER-065; that Keros may be delayed in initiating, enrolling or completing any clinical trials; competition from third parties that are developing products for similar uses; Keros' ability to obtain, maintain and protect its intellectual property; and Keros' dependence on third parties in connection with manufacturing, clinical trials and preclinical studies.

    These and other risks are described more fully in Keros' filings with the Securities and Exchange Commission ("SEC"), including the "Risk Factors" section of the Company's Quarterly Report on Form 10-Q, filed with the SEC on May 8, 2024, and its other documents subsequently filed with or furnished to the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, Keros undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

    Investor Contact:

    Justin Frantz

    [email protected]

    617-221-6042



    KEROS THERAPEUTICS, INC.

    Condensed Consolidated Statements of Operations

    (In thousands, except share and per share data)

    (Unaudited)
     THREE MONTHS ENDED

    JUNE 30,
     SIX MONTHS ENDED

    JUNE 30,
     2024   2023   2024   2023 
    REVENUE:       
    Service and other revenue 37   —   120   — 
    Total revenue 37   —   120   — 
    OPERATING EXPENSES:       
    Research and development (40,515)  (32,534)  (78,773)  (63,625)
    General and administrative (9,961)  (8,803)  (20,269)  (16,581)
    Total operating expenses (50,476)  (41,337)  (99,042)  (80,206)
    LOSS FROM OPERATIONS (50,439)  (41,337)  (98,922)  (80,206)
    OTHER INCOME (EXPENSE), NET       
    Dividend income 5,378   3,987   11,184   7,093 
    Other expense, net (196)  (155)  (633)  (196)
    Total other income, net 5,182   3,832   10,551   6,897 
    Net loss$(45,257) $(37,505) $(88,371) $(73,309)
    Net loss attributable to common stockholders—basic and diluted$(45,257) $(37,505) $(88,371) $(73,309)
    Net loss per share attributable to common stockholders—basic and diluted$(1.25) $(1.27) $(2.46) $(2.53)
    Weighted-average common stock outstanding—basic and diluted 36,103,187   29,602,458   35,894,305   28,989,361 



    KEROS THERAPEUTICS, INC.

    Condensed Consolidated Balance Sheets

    (In thousands, except share and per share data)

    (Unaudited)
     JUNE 30,

    2024
     DECEMBER 31,

    2023
    ASSETS   
    CURRENT ASSETS:   
    Cash and cash equivalents405,863  331,147 
    Accounts receivable4  143 
    Prepaid expenses and other current assets26,847  16,003 
    Total current assets432,714  347,293 
    Operating lease right-of-use assets14,649  15,334 
    Property and equipment, net4,292  4,134 
    Restricted cash1,212  1,212 
    Other long-term assets2,155  2,052 
    TOTAL ASSETS455,022  370,025 
    LIABILITIES AND STOCKHOLDERS' EQUITY   
    CURRENT LIABILITIES:   
    Accounts payable6,535  5,450 
    Current portion of operating lease liabilities1,096  1,005 
    Accrued expenses and other current liabilities13,614  17,918 
    Total current liabilities21,245  24,373 
    Operating lease liabilities, net of current portion12,861  13,439 
    Total liabilities34,106  37,812 
    STOCKHOLDERS' EQUITY:   
    Preferred stock, par value of $0.0001 per share; 10,000,000 shares authorized as of June 30, 2024 and December 31, 2023; no shares issued and outstanding—  — 
    Common stock, par value of $0.0001 per share; 200,000,000 shares authorized as of June 30, 2024 and December 31, 2023; 36,169,558 and 31,841,084 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively3  3 
    Additional paid-in capital890,710  713,636 
    Accumulated deficit(469,797) (381,426)
    Total stockholders' equity420,916  332,213 
    TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY455,022  370,025 


    Primary Logo

    Get the next $KROS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KROS

    DatePrice TargetRatingAnalyst
    6/10/2025$18.00Buy → Neutral
    BofA Securities
    1/21/2025Overweight → Neutral
    Cantor Fitzgerald
    1/17/2025$15.00Outperform → Neutral
    Wedbush
    12/16/2024$102.00 → $63.00Outperform
    Oppenheimer
    12/16/2024Buy → Neutral
    Guggenheim
    12/13/2024$100.00 → $47.00Buy
    H.C. Wainwright
    12/12/2024Buy → Hold
    TD Cowen
    12/12/2024Outperform → Mkt Perform
    William Blair
    More analyst ratings

    $KROS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Adar1 Capital Management, Llc bought $328,127 worth of shares (34,925 units at $9.40) (SEC Form 4)

      4 - Keros Therapeutics, Inc. (0001664710) (Issuer)

      4/11/25 9:57:19 PM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KROS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ADAR1 Issues Statement on Keros Therapeutics' Troubling 2025 Director Election Results and Insufficient Capital Return Proposal

      Significant Withhold Votes from Directors Mary Ann Gray and Alpna Seth Underscores Need for Change and a More Disciplined Capital Allocation Strategy AUSTIN, Texas, June 9, 2025 /PRNewswire/ -- ADAR1 Capital Management, LLC (together with its affiliates, "ADAR1" or "We"), the largest stockholder of Keros Therapeutics (NASDAQ:KROS) ("Keros" or the "Company"), today issued the following statement regarding the results of the Company's 2025 Annual Meeting of Stockholders (the "Annual Meeting"): "We believe the outcome of the Annual Meeting underscores what we have consistently conveyed to Keros' Board of Directors: there is broad and growing concern among stockholders regarding the Board's cap

      6/9/25 3:12:00 PM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Keros Announces Return of $375 Million in Excess Capital to Stockholders

      LEXINGTON, Mass., June 09, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced that the Company has concluded its previously announced review process to evaluate strategic alternatives to maximize stockholder value for the Company. As a result of this process, the Company's Board of Directors (the "Board") unanimously determined to initiate a process to return $375 million o

      6/9/25 6:55:00 AM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference

      LEXINGTON, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced that Keros' Chair and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate in a fireside chat presentation at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025 at 9:20 a.m. Eastern time. A live audio webcast of the fireside chat presentation will be available at h

      6/6/25 4:01:00 PM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KROS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Large owner Adar1 Capital Management, Llc

      4 - Keros Therapeutics, Inc. (0001664710) (Issuer)

      6/12/25 4:51:24 PM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 4 filed by Director Kariv Tomer

      4/A - Keros Therapeutics, Inc. (0001664710) (Issuer)

      6/11/25 7:45:35 AM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 4 filed by Director Nussbaum Ran

      4/A - Keros Therapeutics, Inc. (0001664710) (Issuer)

      6/11/25 7:30:07 AM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KROS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Keros Therapeutics downgraded by BofA Securities with a new price target

      BofA Securities downgraded Keros Therapeutics from Buy to Neutral and set a new price target of $18.00

      6/10/25 7:53:18 AM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Keros Therapeutics downgraded by Cantor Fitzgerald

      Cantor Fitzgerald downgraded Keros Therapeutics from Overweight to Neutral

      1/21/25 7:51:46 AM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Keros Therapeutics downgraded by Wedbush with a new price target

      Wedbush downgraded Keros Therapeutics from Outperform to Neutral and set a new price target of $15.00

      1/17/25 11:09:49 AM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care